Header Logo

Connection

CHRISTIE BALLANTYNE to Atherosclerosis

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Atherosclerosis.
CHRISTIE BALLANTYNE
Connection Strength
22.365
Atherosclerosis
  1. Lipoprotein(a) and Risk of Incident Atherosclerotic Cardiovascular Disease: Impact of High-Sensitivity C-Reactive Protein and Risk Variability Among Human Clinical Subgroups. Nutrients. 2025 Apr 11; 17(8).
    View in: PubMed
    Score: 0.527
  2. Lipoprotein(a) levels in a population with clinical atherosclerotic cardiovascular disease in the United States: A subanalysis from the Lp(a)HERITAGE study. J Clin Lipidol. 2025 Jan-Feb; 19(1):28-38.
    View in: PubMed
    Score: 0.514
  3. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2023 11 09; 30(16):1731-1740.
    View in: PubMed
    Score: 0.477
  4. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med. 2023 09; 29(9):2216-2223.
    View in: PubMed
    Score: 0.470
  5. Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African Americans: The pooling project. Atherosclerosis. 2023 02; 367:15-23.
    View in: PubMed
    Score: 0.451
  6. Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2022 06; 350:82-89.
    View in: PubMed
    Score: 0.429
  7. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol. 2022 07 01; 174:1-11.
    View in: PubMed
    Score: 0.429
  8. How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management? Curr Atheroscler Rep. 2021 04 01; 23(6):28.
    View in: PubMed
    Score: 0.398
  9. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clin Chem. 2021 01 08; 67(1):143-153.
    View in: PubMed
    Score: 0.392
  10. Letter by Wu and Ballantyne Regarding Article, "Protein Kinase C? via Activating Transcription Factor 2-Mediated CD36 Expression and Foam Cell Formation of Ly6Chi Cells Contributes to Atherosclerosis". Circulation. 2019 04 23; 139(17):2077-2078.
    View in: PubMed
    Score: 0.348
  11. Low-Density Lipoprotein Cholesterol: Is 160 the New 190? Circulation. 2018 11 20; 138(21):2326-2329.
    View in: PubMed
    Score: 0.338
  12. Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia. Nat Rev Cardiol. 2017 07; 14(7):385-386.
    View in: PubMed
    Score: 0.304
  13. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
    View in: PubMed
    Score: 0.304
  14. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016 10; 253:81-87.
    View in: PubMed
    Score: 0.289
  15. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1069-77.
    View in: PubMed
    Score: 0.243
  16. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan; 232(1):86-93.
    View in: PubMed
    Score: 0.238
  17. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study. Clin Chem. 2013 Dec; 59(12):1802-10.
    View in: PubMed
    Score: 0.236
  18. Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study. Circ Heart Fail. 2013 Sep 01; 6(5):936-43.
    View in: PubMed
    Score: 0.233
  19. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke. 2013 Apr; 44(4):961-7.
    View in: PubMed
    Score: 0.228
  20. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011 Apr 05; 123(13):1367-76.
    View in: PubMed
    Score: 0.199
  21. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010 Apr 13; 55(15):1600-7.
    View in: PubMed
    Score: 0.186
  22. Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation. 2009 May 26; 119(20):2708-17.
    View in: PubMed
    Score: 0.175
  23. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009 Feb; 40(2):376-81.
    View in: PubMed
    Score: 0.170
  24. Low-density lipoprotein and high-density lipoprotein cholesterol levels in relation to genetic polymorphisms and menopausal status: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2008 Oct; 200(2):322-8.
    View in: PubMed
    Score: 0.160
  25. How to identify patients with vulnerable plaques. Diabetes Obes Metab. 2008 Sep; 10(10):824-33.
    View in: PubMed
    Score: 0.157
  26. Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. World J Surg. 2007 Apr; 31(4):695-704.
    View in: PubMed
    Score: 0.151
  27. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2007 Feb; 30(2):325-31.
    View in: PubMed
    Score: 0.149
  28. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005 Nov 28; 165(21):2479-84.
    View in: PubMed
    Score: 0.138
  29. A Metabolomics Study of Cardiac Dysfunction in Hyperglycemia: Findings From the Atherosclerosis Risk in Communities (ARIC) Study and the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Diabetes Care. 2025 Sep 01; 48(9):1589-1597.
    View in: PubMed
    Score: 0.135
  30. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
    View in: PubMed
    Score: 0.135
  31. Adipokines and Transitions in Metabolic Health Over Time: The Atherosclerosis Risk In Communities (ARIC) Study. J Clin Endocrinol Metab. 2025 Aug 07; 110(9):e2939-e2945.
    View in: PubMed
    Score: 0.135
  32. LDL cholesterol management simplified in adults-lower for longer is better: Guidance from the National Lipid Association. J Clin Lipidol. 2025 Sep-Oct; 19(5):1200-1207.
    View in: PubMed
    Score: 0.133
  33. Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi-Ethnic Study of Atherosclerosis: The Pooling Project. J Am Heart Assoc. 2025 Jun 03; 14(11):e038608.
    View in: PubMed
    Score: 0.133
  34. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis. 2005 Dec; 183(2):301-7.
    View in: PubMed
    Score: 0.132
  35. Foamy monocytes and atherogenesis in mice with combined hyperlipidemia and effects of antisense knockdown of apoCIII. J Lipid Res. 2025 Apr; 66(4):100763.
    View in: PubMed
    Score: 0.130
  36. Early-onset atherosclerotic cardiovascular disease. Eur J Prev Cardiol. 2025 Jan 27; 32(2):100-112.
    View in: PubMed
    Score: 0.130
  37. Association of left atrial function with frailty: The Atherosclerosis Risk in Communities (ARIC) study. J Am Geriatr Soc. 2024 Dec; 72(12):3810-3823.
    View in: PubMed
    Score: 0.126
  38. Anemia, Iron Deficiency, and Cause-Specific Mortality: The Atherosclerosis Risk in Communities Study. Gerontology. 2024; 70(10):1023-1032.
    View in: PubMed
    Score: 0.125
  39. Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study. Circulation. 2024 Jul 16; 150(3):250-252.
    View in: PubMed
    Score: 0.125
  40. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
    View in: PubMed
    Score: 0.123
  41. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort. J Am Coll Cardiol. 2024 Apr 23; 83(16):1511-1525.
    View in: PubMed
    Score: 0.123
  42. Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol. JAMA Cardiol. 2024 Mar 01; 9(3):263-271.
    View in: PubMed
    Score: 0.122
  43. Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024 02 06; 83(5):562-573.
    View in: PubMed
    Score: 0.121
  44. A polygenic risk score of atrial fibrillation improves prediction of lifetime risk for heart failure. ESC Heart Fail. 2024 Apr; 11(2):1086-1096.
    View in: PubMed
    Score: 0.121
  45. Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure development. Nat Commun. 2024 Jan 15; 15(1):528.
    View in: PubMed
    Score: 0.121
  46. Novel Size-Based High-Density Lipoprotein Subspecies and Incident Vascular Events. J Am Heart Assoc. 2023 11 07; 12(21):e031160.
    View in: PubMed
    Score: 0.119
  47. Age-Related Differences in the Contribution of Systolic Blood Pressure and Biomarkers to Cardiovascular Disease Risk Prediction: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Cardiol. 2023 10 01; 204:295-301.
    View in: PubMed
    Score: 0.117
  48. Coronary heart disease and ischemic stroke polygenic risk scores and atherosclerotic cardiovascular disease in a diverse, population-based cohort study. PLoS One. 2023; 18(6):e0285259.
    View in: PubMed
    Score: 0.116
  49. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.
    View in: PubMed
    Score: 0.115
  50. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study. Circ Heart Fail. 2023 05; 16(5):e009694.
    View in: PubMed
    Score: 0.115
  51. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry. J Am Heart Assoc. 2023 05 02; 12(9):e029175.
    View in: PubMed
    Score: 0.115
  52. Proteomic Predictors of Incident Diabetes: Results From the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2023 04 01; 46(4):733-741.
    View in: PubMed
    Score: 0.114
  53. Growth Differentiation Factor 15 and Risk of Bleeding Events: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2023 03 21; 12(6):e023847.
    View in: PubMed
    Score: 0.114
  54. Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes Obes Metab. 2023 06; 25(6):1750-1757.
    View in: PubMed
    Score: 0.114
  55. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease. Circulation. 2023 05 02; 147(18):1411-1413.
    View in: PubMed
    Score: 0.114
  56. Missense Genetic Variation of ICAM1 and Incident Heart Failure. J Card Fail. 2023 08; 29(8):1163-1172.
    View in: PubMed
    Score: 0.114
  57. Association of Long-term Change in N-Terminal Pro-B-Type Natriuretic Peptide With Incident Heart Failure and Death. JAMA Cardiol. 2023 03 01; 8(3):222-230.
    View in: PubMed
    Score: 0.114
  58. Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers: The ARIC Study. JACC Heart Fail. 2023 04; 11(4):440-450.
    View in: PubMed
    Score: 0.113
  59. Comparison of Proteomic Measurements Across Platforms in the Atherosclerosis Risk in Communities (ARIC) Study. Clin Chem. 2023 01 04; 69(1):68-79.
    View in: PubMed
    Score: 0.112
  60. Primary Prevention Management of Elevated Lipoprotein(a). JAMA Cardiol. 2023 01 01; 8(1):96-97.
    View in: PubMed
    Score: 0.112
  61. A proteomic approach for investigating the pleiotropic effects of statins in the atherosclerosis risk in communities (ARIC) study. J Proteomics. 2023 02 10; 272:104788.
    View in: PubMed
    Score: 0.112
  62. Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia. J Clin Lipidol. 2023 Jan-Feb; 17(1):150-156.
    View in: PubMed
    Score: 0.112
  63. Importance of NT-proBNP and conventional risk factors for prediction of death in older adults with and without diabetes mellitus- A report from the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Res Clin Pract. 2022 Dec; 194:110164.
    View in: PubMed
    Score: 0.112
  64. Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2022 11; 11(21):e026762.
    View in: PubMed
    Score: 0.111
  65. Testican-2 Is Associated with Reduced Risk of Incident ESKD. J Am Soc Nephrol. 2023 01 01; 34(1):122-131.
    View in: PubMed
    Score: 0.111
  66. Diabetes Duration and Subclinical Myocardial Injury: The Atherosclerosis Risk in Communities Study (ARIC). Clin Chem. 2022 10 06; 68(10):1272-1280.
    View in: PubMed
    Score: 0.111
  67. Statin Use and Risk of Diabetes by Subclinical Atherosclerosis Burden (from a Multi-Ethnic Study of Atherosclerosis Report). Am J Cardiol. 2022 12 01; 184:7-13.
    View in: PubMed
    Score: 0.110
  68. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD). Clin Cardiol. 2022 Dec; 45(12):1303-1310.
    View in: PubMed
    Score: 0.110
  69. Long-term changes in plasma proteomic profiles in premenopausal and postmenopausal Black and White women: the Atherosclerosis Risk in Communities study. Menopause. 2022 10 01; 29(10):1150-1160.
    View in: PubMed
    Score: 0.110
  70. Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: The multi-ethnic study of atherosclerosis. Prog Cardiovasc Dis. 2022 Sep-Oct; 74:19-27.
    View in: PubMed
    Score: 0.109
  71. Growth Differentiation Factor 15 and the Subsequent Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. Clin Chem. 2022 07 27; 68(8):1084-1093.
    View in: PubMed
    Score: 0.109
  72. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1?, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation. 2022 08 02; 146(5):372-379.
    View in: PubMed
    Score: 0.109
  73. Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2022 06 07; 11(11):e024870.
    View in: PubMed
    Score: 0.108
  74. Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlr-/- Mice. Cells. 2022 05 30; 11(11).
    View in: PubMed
    Score: 0.108
  75. Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study. Hypertension. 2022 09; 79(9):1984-1993.
    View in: PubMed
    Score: 0.108
  76. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. Eur J Prev Cardiol. 2022 03 11; 29(2):e53-e64.
    View in: PubMed
    Score: 0.106
  77. Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study. Diabetologia. 2022 06; 65(6):955-963.
    View in: PubMed
    Score: 0.106
  78. Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol. 2021 12 15; 161:42-50.
    View in: PubMed
    Score: 0.105
  79. Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. Circulation. 2022 01 25; 145(4):259-267.
    View in: PubMed
    Score: 0.104
  80. Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. Am J Med. 2022 05; 135(5):603-606.
    View in: PubMed
    Score: 0.104
  81. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
    View in: PubMed
    Score: 0.103
  82. Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia. J Am Heart Assoc. 2021 09 07; 10(17):e020890.
    View in: PubMed
    Score: 0.102
  83. What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. J Am Heart Assoc. 2021 08 17; 10(16):e020893.
    View in: PubMed
    Score: 0.102
  84. Duration of Diabetes and Incident?Heart?Failure: The ARIC (Atherosclerosis Risk In Communities) Study. JACC Heart Fail. 2021 08; 9(8):594-603.
    View in: PubMed
    Score: 0.102
  85. The ARIC (Atherosclerosis Risk In Communities) Study: JACC Focus Seminar 3/8. J Am Coll Cardiol. 2021 06 15; 77(23):2939-2959.
    View in: PubMed
    Score: 0.101
  86. Glycated Hemoglobin to Detect Subclinical Atherosclerosis in People Without Diabetes. J Am Coll Cardiol. 2021 06 08; 77(22):2792-2795.
    View in: PubMed
    Score: 0.101
  87. High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2021 07; 44(7):1657-1663.
    View in: PubMed
    Score: 0.100
  88. Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease. Am J Med. 2021 08; 134(8):1047-1051.e2.
    View in: PubMed
    Score: 0.100
  89. Growth Differentiation Factor (GDF)-15 and Cardiometabolic Outcomes among Older Adults: The Atherosclerosis Risk in Communities Study. Clin Chem. 2021 03 31; 67(4):653-661.
    View in: PubMed
    Score: 0.100
  90. Recreational substance use among patients with premature atherosclerotic cardiovascular disease. Heart. 2021 04; 107(8):650-656.
    View in: PubMed
    Score: 0.099
  91. Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2021 05 01; 146:15-21.
    View in: PubMed
    Score: 0.098
  92. Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affair Healthcare System. Cardiovasc Drugs Ther. 2022 04; 36(2):295-300.
    View in: PubMed
    Score: 0.098
  93. Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther. 2022 02; 36(1):93-102.
    View in: PubMed
    Score: 0.098
  94. Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. J Am Heart Assoc. 2020 11 17; 9(22):e017915.
    View in: PubMed
    Score: 0.097
  95. High-Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults. J Am Geriatr Soc. 2021 04; 69(4):986-994.
    View in: PubMed
    Score: 0.097
  96. Associations of 1,5-Anhydroglucitol and 2-Hour Glucose with Major Clinical Outcomes in the Atherosclerosis Risk in Communities (ARIC) Study. J Appl Lab Med. 2020 11 01; 5(6):1296-1306.
    View in: PubMed
    Score: 0.097
  97. Sex Hormones and Incident Heart Failure in Men and Postmenopausal Women: The Atherosclerosis Risk in Communities Study. J Clin Endocrinol Metab. 2020 10 01; 105(10).
    View in: PubMed
    Score: 0.096
  98. Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
    View in: PubMed
    Score: 0.096
  99. Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2020 08 03; 3(8):e2011051.
    View in: PubMed
    Score: 0.095
  100. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Curr Atheroscler Rep. 2020 06 03; 22(7):25.
    View in: PubMed
    Score: 0.094
  101. Physical Activity and Incident Heart Failure in High-Risk Subgroups: The ARIC Study. J Am Heart Assoc. 2020 05 18; 9(10):e014885.
    View in: PubMed
    Score: 0.094
  102. JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes. J Clin Lipidol. 2020 Jan - Feb; 14(1):4-15.
    View in: PubMed
    Score: 0.091
  103. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. Am Heart J. 2020 01; 219:70-77.
    View in: PubMed
    Score: 0.090
  104. Replacing Saturated Fat With Unsaturated Fat in Western Diet Reduces Foamy Monocytes and Atherosclerosis in Male Ldlr-/- Mice. Arterioscler Thromb Vasc Biol. 2020 01; 40(1):72-85.
    View in: PubMed
    Score: 0.090
  105. Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17?180 Individuals. Circ Res. 2019 09 27; 125(8):773-782.
    View in: PubMed
    Score: 0.089
  106. The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. J Clin Lipidol. 2019 Sep - Oct; 13(5):797-803.e1.
    View in: PubMed
    Score: 0.089
  107. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
    View in: PubMed
    Score: 0.089
  108. High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. J Am Geriatr Soc. 2019 11; 67(11):2353-2361.
    View in: PubMed
    Score: 0.089
  109. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgrad Med. 2019 Aug; 131(6):390-396.
    View in: PubMed
    Score: 0.089
  110. Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities Study. J Am Geriatr Soc. 2019 09; 67(9):1795-1802.
    View in: PubMed
    Score: 0.088
  111. Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation. 2019 08 13; 140(7):618-620.
    View in: PubMed
    Score: 0.088
  112. Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2019 07 15; 124(2):245-252.
    View in: PubMed
    Score: 0.087
  113. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
    View in: PubMed
    Score: 0.086
  114. Reproducibility and Variability of Protein Analytes Measured Using a Multiplexed Modified Aptamer Assay. J Appl Lab Med. 2019 07; 4(1):30-39.
    View in: PubMed
    Score: 0.086
  115. Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study. Thromb Haemost. 2018 Nov; 118(11):1940-1950.
    View in: PubMed
    Score: 0.084
  116. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018 10 07; 39(38):3499-3507.
    View in: PubMed
    Score: 0.084
  117. Diagnostic Performance of 1,5-Anhydroglucitol Compared to 2-H Glucose in the Atherosclerosis Risk in Communities Study. Clin Chem. 2018 10; 64(10):1536-1537.
    View in: PubMed
    Score: 0.083
  118. The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. Neurobiol Aging. 2018 08; 68:26-33.
    View in: PubMed
    Score: 0.081
  119. Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. JAMA Cardiol. 2018 03 01; 3(3):200-206.
    View in: PubMed
    Score: 0.080
  120. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
    View in: PubMed
    Score: 0.080
  121. Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2017 Dec 15; 6(12).
    View in: PubMed
    Score: 0.079
  122. SES, Heart Failure, and N-terminal Pro-b-type Natriuretic Peptide: The Atherosclerosis Risk in Communities Study. Am J Prev Med. 2018 02; 54(2):229-236.
    View in: PubMed
    Score: 0.079
  123. Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 02 15; 121(4):430-436.
    View in: PubMed
    Score: 0.079
  124. Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease: The Atherosclerosis Risk in Communities Study. Stroke. 2017 12; 48(12):3196-3202.
    View in: PubMed
    Score: 0.079
  125. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 09 21; 377(12):1119-1131.
    View in: PubMed
    Score: 0.078
  126. Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2017 Oct; 192:19-25.
    View in: PubMed
    Score: 0.077
  127. The Upregulation of Integrin aD?2 (CD11d/CD18) on Inflammatory Macrophages Promotes Macrophage Retention in Vascular Lesions and Development of Atherosclerosis. J Immunol. 2017 06 15; 198(12):4855-4867.
    View in: PubMed
    Score: 0.076
  128. Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. Circulation. 2017 05 30; 135(22):2204-2206.
    View in: PubMed
    Score: 0.076
  129. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis. 2017 06; 261:12-18.
    View in: PubMed
    Score: 0.076
  130. Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. Curr Cardiol Rep. 2017 03; 19(3):19.
    View in: PubMed
    Score: 0.075
  131. Serum vitamin D and change in lipid levels over 5?y: The Atherosclerosis Risk in Communities study. Nutrition. 2017 Jun; 38:85-93.
    View in: PubMed
    Score: 0.075
  132. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. Int J Cardiol. 2017 Apr 15; 233:61-66.
    View in: PubMed
    Score: 0.075
  133. High-Sensitivity Cardiac Troponin T (hs-cTnT) as a Predictor of Incident Diabetes in the Atherosclerosis Risk in Communities Study. Diabetes Care. 2017 Feb; 40(2):261-269.
    View in: PubMed
    Score: 0.074
  134. Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis. 2016 10; 253:156-163.
    View in: PubMed
    Score: 0.072
  135. Alcohol Consumption and Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study. Clin Chem. 2016 09; 62(9):1202-10.
    View in: PubMed
    Score: 0.072
  136. Defective Association of the Platelet Glycoprotein Ib-IX Complex with the Glycosphingolipid-Enriched Membrane Domain Inhibits Murine Thrombus and Atheroma Formation. J Immunol. 2016 07 01; 197(1):288-95.
    View in: PubMed
    Score: 0.071
  137. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 07 05; 68(1):92-125.
    View in: PubMed
    Score: 0.070
  138. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016 May-Jun; 10(3):635-645.e1.
    View in: PubMed
    Score: 0.070
  139. Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study. PLoS One. 2016; 11(2):e0148765.
    View in: PubMed
    Score: 0.070
  140. N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2016 Feb 16; 133(7):631-8.
    View in: PubMed
    Score: 0.069
  141. Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2016 May; 39(5):677-85.
    View in: PubMed
    Score: 0.069
  142. Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis. Clin Chem. 2015 Dec; 61(12):1524-31.
    View in: PubMed
    Score: 0.068
  143. Validity of self-report of lipid medication use: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2015 Oct; 242(2):625-9.
    View in: PubMed
    Score: 0.067
  144. Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study. Am Heart J. 2015 Nov; 170(5):961-7.
    View in: PubMed
    Score: 0.067
  145. Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults: Atherosclerosis Risk in Communities Study. Hypertension. 2015 Sep; 66(3):474-80.
    View in: PubMed
    Score: 0.067
  146. Foamy monocytes form early and contribute to nascent atherosclerosis in mice with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2015 Aug; 35(8):1787-97.
    View in: PubMed
    Score: 0.067
  147. Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. J Am Heart Assoc. 2015 May 21; 4(5).
    View in: PubMed
    Score: 0.066
  148. Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence. Clin Chem. 2015 Jul; 61(7):938-47.
    View in: PubMed
    Score: 0.066
  149. Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: The Atherosclerosis Risk in Communities Cohort Study. Int J Cardiol. 2015; 187:651-7.
    View in: PubMed
    Score: 0.066
  150. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis. 2015 Jun; 240(2):490-6.
    View in: PubMed
    Score: 0.066
  151. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort. JAMA Intern Med. 2015 Jan; 175(1):138-40.
    View in: PubMed
    Score: 0.065
  152. FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. JACC Cardiovasc Imaging. 2015 Apr; 8(4):493-494.
    View in: PubMed
    Score: 0.064
  153. Association of body mass index and waist circumference with subclinical atherosclerosis in retired NFL players. South Med J. 2014 Oct; 107(10):633-9.
    View in: PubMed
    Score: 0.063
  154. Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrol Dial Transplant. 2015 Jan; 30(1):77-83.
    View in: PubMed
    Score: 0.063
  155. Review of clinical practice guidelines for the management of LDL-related risk. J Am Coll Cardiol. 2014 Jul 15; 64(2):196-206.
    View in: PubMed
    Score: 0.063
  156. Validated context-dependent associations of coronary heart disease risk with genotype variation in the chromosome 9p21 region: the Atherosclerosis Risk in Communities study. Hum Genet. 2014 Sep; 133(9):1105-16.
    View in: PubMed
    Score: 0.062
  157. High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. Eur Heart J. 2014 Jul 14; 35(27):1817-24.
    View in: PubMed
    Score: 0.061
  158. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014 Apr; 35(15):960-8.
    View in: PubMed
    Score: 0.061
  159. Troponin T, NT-proBNP, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Vasc Med. 2014 Feb; 19(1):33-41.
    View in: PubMed
    Score: 0.061
  160. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke. 2013 Jul; 44(7):1803-8.
    View in: PubMed
    Score: 0.058
  161. Lactate and risk of incident diabetes in a case-cohort of the atherosclerosis risk in communities (ARIC) study. PLoS One. 2013; 8(1):e55113.
    View in: PubMed
    Score: 0.057
  162. Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study. PLoS One. 2012; 7(12):e51237.
    View in: PubMed
    Score: 0.056
  163. Association of genome-wide variation with highly sensitive cardiac troponin-T levels in European Americans and Blacks: a meta-analysis from atherosclerosis risk in communities and cardiovascular health studies. Circ Cardiovasc Genet. 2013 Feb; 6(1):82-8.
    View in: PubMed
    Score: 0.056
  164. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol. 2012 Feb; 5(1):155-62.
    View in: PubMed
    Score: 0.052
  165. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects?on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
    View in: PubMed
    Score: 0.052
  166. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012 Jan 17; 125(2):241-9.
    View in: PubMed
    Score: 0.052
  167. Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) study. Circ Cardiovasc Genet. 2012 Feb 01; 5(1):73-80.
    View in: PubMed
    Score: 0.052
  168. Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2012 Jan; 43(1):103-8.
    View in: PubMed
    Score: 0.052
  169. Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet. 2011 Sep 11; 43(10):940-7.
    View in: PubMed
    Score: 0.051
  170. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011 Nov-Dec; 5(6):474-82.
    View in: PubMed
    Score: 0.050
  171. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. Clin Chem. 2011 Jun; 57(6):891-7.
    View in: PubMed
    Score: 0.050
  172. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Curr Med Res Opin. 2011 Jun; 27(6):1119-29.
    View in: PubMed
    Score: 0.050
  173. Intercellular adhesion molecule-1 G241R polymorphism predicts risk of incident ischemic stroke: Atherosclerosis Risk in Communities study. Stroke. 2010 May; 41(5):1038-40.
    View in: PubMed
    Score: 0.046
  174. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. J Lipid Res. 2009 Aug; 50(8):1685-91.
    View in: PubMed
    Score: 0.043
  175. Genetic variation and decreased risk for obesity in the Atherosclerosis Risk in Communities Study. Diabetes Obes Metab. 2007 Jul; 9(4):548-57.
    View in: PubMed
    Score: 0.038
  176. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2008 Feb; 196(2):926-30.
    View in: PubMed
    Score: 0.038
  177. Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. Atherosclerosis. 2007 Aug; 193(2):283-91.
    View in: PubMed
    Score: 0.036
  178. Apolipoprotein E genotype and incident ischemic stroke: the Atherosclerosis Risk in Communities Study. Stroke. 2005 Nov; 36(11):2484-6.
    View in: PubMed
    Score: 0.034
  179. Epigenome-wide DNA methylation association study of CHIP provides insight into perturbed gene regulation. Nat Commun. 2025 May 20; 16(1):4678.
    View in: PubMed
    Score: 0.033
  180. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
    View in: PubMed
    Score: 0.033
  181. Long-term longitudinal analysis of 4,187 participants reveals insights into determinants of clonal hematopoiesis. Nat Commun. 2024 09 09; 15(1):7858.
    View in: PubMed
    Score: 0.032
  182. Associations of mid-to-late-life inflammation with late-life mobility and the influences of chronic comorbidities, race, and social determinants of health: The Atherosclerosis Risk in Communities Study. J Am Geriatr Soc. 2024 Aug; 72(8):2434-2445.
    View in: PubMed
    Score: 0.031
  183. Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA. 2024 06 11; 331(22):1898-1909.
    View in: PubMed
    Score: 0.031
  184. High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes. Diabetes Care. 2020 10; 43(10):e144-e146.
    View in: PubMed
    Score: 0.024
  185. Performance of High-Sensitivity Cardiac Troponin Assays to Reflect Comorbidity Burden and Improve Mortality Risk Stratification in Older Adults With Diabetes. Diabetes Care. 2020 06; 43(6):1200-1208.
    View in: PubMed
    Score: 0.023
  186. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.023
  187. Mortality Implications of Prediabetes and Diabetes in Older Adults. Diabetes Care. 2020 02; 43(2):382-388.
    View in: PubMed
    Score: 0.023
  188. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. J Am Coll Cardiol. 2019 10 15; 74(15):1926-1942.
    View in: PubMed
    Score: 0.022
  189. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). Am J Cardiol. 2019 09 01; 124(5):696-701.
    View in: PubMed
    Score: 0.022
  190. Metabolomic Pattern Predicts Incident Coronary Heart Disease. Arterioscler Thromb Vasc Biol. 2019 07; 39(7):1475-1482.
    View in: PubMed
    Score: 0.022
  191. ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
    View in: PubMed
    Score: 0.022
  192. Weight History and Subclinical Myocardial Damage. Clin Chem. 2018 01; 64(1):201-209.
    View in: PubMed
    Score: 0.020
  193. Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study. Neurology. 2017 Nov 28; 89(22):2262-2270.
    View in: PubMed
    Score: 0.020
  194. A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience. J Clin Lipidol. 2017 May - Jun; 11(3):596-599.
    View in: PubMed
    Score: 0.019
  195. Obesity and Subtypes of Incident Cardiovascular Disease. J Am Heart Assoc. 2016 07 28; 5(8).
    View in: PubMed
    Score: 0.018
  196. The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2016 09; 23(14):1529-36.
    View in: PubMed
    Score: 0.017
  197. The Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study. Am J Epidemiol. 2016 Mar 01; 183(5):452-61.
    View in: PubMed
    Score: 0.017
  198. Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. Atherosclerosis. 2015 Aug; 241(2):641-8.
    View in: PubMed
    Score: 0.017
  199. Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015 Aug 18; 132(7):578-85.
    View in: PubMed
    Score: 0.017
  200. sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Diabetes Complications. 2015 Mar; 29(2):180-5.
    View in: PubMed
    Score: 0.016
  201. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. Hypertension. 2015 Jan; 65(1):78-84.
    View in: PubMed
    Score: 0.016
  202. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2015 Jan; 169(1):31-8.e3.
    View in: PubMed
    Score: 0.016
  203. Analysis of multiple association studies provides evidence of an expression QTL hub in gene-gene interaction network affecting HDL cholesterol levels. PLoS One. 2014; 9(3):e92469.
    View in: PubMed
    Score: 0.015
  204. Retinol binding protein 4 and incident diabetes--the Atherosclerosis Risk in Communities Study (ARIC Study). Rev Bras Epidemiol. 2013 Jun; 16(2):388-97.
    View in: PubMed
    Score: 0.014
  205. Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrol Dial Transplant. 2012 Jul; 27(7):2839-47.
    View in: PubMed
    Score: 0.013
  206. Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study. Int J Epidemiol. 2010 Dec; 39(6):1647-55.
    View in: PubMed
    Score: 0.012
  207. Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet. 2009 Jun; 2(3):279-85.
    View in: PubMed
    Score: 0.011
  208. Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2007 Nov; 195(1):e76-82.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.